1. Home
  2. Category
  3. Symptoms/Side Effects

Peripheral Neuropathy

CNE Article

Extremity Cooling: A Synthesis of Cryotherapy Interventions to Reduce Peripheral Neuropathy and Nail Changes From Taxane-Based Chemotherapy

Lauren Peyton
Erica Fischer-Cartlidge
CJON 2019, 23(5), 522-528 DOI: 10.1188/19.CJON.522-528
Background: Taxane-based chemotherapies are frequently used to treat solid tumor cancers. Two significant side effects include nail changes and/or peripheral neuropathy. These side effects can cause pain, infections, dose reductions, and treatment delays, all of which negatively affect quality of...
0
No votes yet
Read this Article
Article

Taxane-Induced Peripheral Neuropathy: Objective and Subjective Comparison Between Paclitaxel and Docetaxel in Patients With Breast Cancer

Ya-Ning Chan
You-Wun Jheng
Pei-Ju Wang
Chin-Yau Chen
Ming-Wei Lin
Ya-Jung Wang
CJON 2019, 23(5), 494-501 DOI: 10.1188/19.CJON.494-501
Background: Taxane-induced peripheral neuropathy (TIPN) is caused by the neurotoxicity of paclitaxel and docetaxel, but the differences between paclitaxel- and docetaxel-induced peripheral neuropathy are understudied. Objectives: The purpose of this study is to compare TIPN between docetaxel and...
0
No votes yet
Read this Article
Article

Chemotherapy-Induced Peripheral Neuropathy: Association With Increased Risk of Falls and Injuries

Estelle Autissier
CJON 2019, 23(4), 405-410 DOI: 10.1188/19.CJON.405-410
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and degenerative side effect of many commonly used chemotherapy agents. Symptoms manifest as sensory and motor neuropathies. CIPN may necessitate chemotherapy dose reduction or discontinuation. Objectives: This review...
0
No votes yet
Read this Article
Online Exclusive Article

Chemotherapy-Induced Peripheral Neuropathy: Use of an Electronic Care Planning System to Improve Adherence to Recommended Assessment and Management Practices

Robert Knoerl
Celia Bridges
Gloria L. Smith
James J. Yang
Grace Kanzawa-Lee
Ellen M.L. Smith
CJON 2018, 22(5), E134-E140 DOI: 10.1188/18.CJON.E134-E140
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is often inadequately assessed and managed by advanced practice providers. Objectives: The aim is to explore the impact of CIPN assessment training and electronic care planning system (CPS) use on CIPN assessment documentation and...
0
No votes yet
Read this Article
Online Exclusive Article

Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events

Kathleen Clifford
Amanda Copeland
Gregory Knutzen
Ellen Samuelson
Laurie Grove
Karen Schiavo
CJON 2018, 22(4), E103-E114 DOI: 10.1188/18.CJON.E103-E114
Background: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30-expressing cells. Objectives: This article assesses the occurrence and management of the most frequent and clinically relevant BV-associated adverse events (AEs), with a focus on Hodgkin lymphoma and systemic...
5
Average: 5 (1 vote)
Read this Article

Questions, Concerns or Requests

We're just a click away for assistance.